Definition And Pathophysiology

• Inherited errors of metabolism resulting from defects in enzymes or transport proteins involved in glycogen synthesis or degradation.
• Pathological accumulation of abnormal quantity or quality of glycogen in tissues such as liver, muscle, and heart.
• Results in energy failure characterized by an inability to liberate glucose from glycogen, leading to fasting hypoglycemia in hepatic types or muscle energy failure in muscular types.

Classification

Key Hepatic Glycogenoses

GSD Type I (Von Gierke Disease)

• Defect: Glucose-6-Phosphatase complex.
  • Type Ia results from deficiency in the catalytic subunit (G6PC).
  • Type Ib results from deficiency in the translocase (SLC37A4).
• Pathophysiology: Inability to convert glucose-6-phosphate to glucose. Excess glucose-6-phosphate shunts into alternative pathways, leading to lactic acidosis via glycolysis, hypertriglyceridemia via lipogenesis, and hyperuricemia via the pentose phosphate pathway.
• Clinical Features: Presents at 3–6 months with seizures and failure to thrive. Features include "doll-like" facies, short stature, massive hepatomegaly, and renomegaly. Splenomegaly is absent.
• Type Ib Nuances: Accompanied by neutropenia, neutrophil dysfunction, recurrent infections, and Crohn-like inflammatory bowel disease.
• Complications: Hepatic adenomas carrying a risk of hepatocellular carcinoma, focal segmental glomerulosclerosis, gout, and pancreatitis.

GSD Type III (Cori/Forbes Disease)

• Defect: Debranching enzyme (Amylo-1,6-glucosidase). Type IIIa involves liver and muscle, while Type IIIb involves liver only.
• Pathophysiology: Accumulation of abnormally structured glycogen called limit dextrin. Gluconeogenesis remains intact.
• Clinical Features: Hepatomegaly that often resolves by puberty, growth retardation, progressive myopathy, and left ventricular hypertrophy.
• Biochemistry: Ketotic hypoglycemia with normal lactate and normal uric acid levels.

GSD Type IV (Andersen Disease)

• Defect: Branching enzyme.
• Pathophysiology: Accumulation of unbranched, insoluble glycogen forming polyglucosan bodies. These act as foreign bodies provoking intense fibrosis.
• Clinical Features: Failure to thrive, hepatosplenomegaly, and rapid progression to cirrhosis and liver failure by age 5.

GSD Type VI (Hers) And IX

• Defect: Liver phosphorylase (Type VI) or phosphorylase kinase (Type IX).
• Clinical Features: Mildest hepatic forms characterized by hepatomegaly, growth retardation, and mild ketotic hypoglycemia. Symptoms typically improve with age.

GSD Type 0

• Defect: Hepatic glycogen synthase.
• Pathophysiology: Inability to synthesize glycogen, resulting in no hepatic glycogen stores.
• Clinical Features: Rapid-onset fasting ketotic hypoglycemia accompanied by post-prandial hyperglycemia and elevated lactate. Hepatomegaly is notably absent, differentiating it from other hepatic GSDs.

Key Muscle Glycogenoses

GSD Type II (Pompe Disease)

• Defect: Lysosomal acid alpha-glucosidase (GAA). Unique as it is both a GSD and a Lysosomal Storage Disorder.
• Pathophysiology: Lysosomal accumulation of glycogen causes lysosomal swelling and cellular rupture in cardiac, skeletal, and smooth muscle.
• Infantile Form (Classic): Presents <6 months with profound hypotonia ("Approach to a floppy infant"), massive hypertrophic cardiomyopathy, macroglossia, and a short PR interval on electrocardiogram. High mortality by 1 year without treatment.
• Late-Onset Form: Proximal limb-girdle muscle weakness and early disproportionate diaphragmatic weakness leading to respiratory failure. Cardiomyopathy is typically absent.

GSD Type V (McArdle Disease)

• Defect: Muscle phosphorylase.
• Clinical Features: Exercise intolerance, muscle cramps, myalgia, and recurrent myoglobinuria carrying a risk of acute kidney injury.
• Second Wind Phenomenon: Improved exercise tolerance after approximately 10 minutes due to the metabolic switch to fatty acid oxidation.

Diagnostic Evaluation

Differential Diagnosis

• Fatty Acid Oxidation Defects (FAOD): Present with fasting hypoketotic hypoglycemia and absent ketones, differentiating them from ketotic hepatic GSDs.
• Organic Acidemias: Present with high anion gap metabolic acidosis and severe hyperammonemia, unlike the lactic acidosis seen in GSD I.
• Urea Cycle Disorders: Feature severe hyperammonemia and respiratory alkalosis without primary hypoglycemia.

Management Principles

Hepatic GSDs

• Therapeutic Goal: Maintain normoglycemia (blood glucose >70 mg/dL) to prevent secondary metabolic shunting.
• Dietary Modification:
  • Frequent feeds every 3–4 hours.
  • Uncooked cornstarch administration (1.6–2.5 g/kg/dose every 4–6 hours) to provide slow-release glucose.
  • Continuous nocturnal gastric drip feeding for infants.
  • Strict avoidance of fructose, sucrose, and galactose in GSD I, as these cannot be converted to glucose and exacerbate lactic acidosis.
• Pharmacotherapy: Allopurinol for hyperuricemia, lipid-lowering agents (fibrates/statins) for hypertriglyceridemia, and ACE inhibitors for microalbuminuria. Granulocyte Colony-Stimulating Factor (G-CSF) or Empagliflozin is used for neutropenia in GSD Ib.
• Surgical: Liver transplantation is curative for the metabolic defect and indicated for poor control or development of multiple adenomas.

Muscle GSDs

• Pompe Disease (Type II): Enzyme Replacement Therapy (ERT) using Alglucosidase alfa is lifesaving for the infantile form and stabilizes late-onset forms. Immunomodulation is required for Cross-Reactive Immunologic Material (CRIM)-negative patients to prevent neutralizing antibody formation.
• McArdle Disease (Type V): Avoidance of strenuous anaerobic exercise. Pre-exercise administration of oral sucrose helps induce the "second wind" phenomenon.